To Aktiliza

Актилизе Drug photo

The description is actual on 05.07.2016

  • Latin name: Actilyse
  • ATH code: B01AD02
  • Active ingredient: Alteplaza (Alteplase)
  • Producer: Bothringer Ingelheim Pharma, GmbH & Co.KG (Germany)


Alteplaza, phosphoric acid, L-arginine, polysorbate.

Release form

Powder for infusions in sterile glass bottles of 50 ml, complete with solvent in bottles on 50 ml; in a cardboard pack.

Pharmacological action


Pharmacodynamics and pharmacokinetics


Drug with thrombolytic effect, is a fabric plasminogen activator (plasminogen)the glycoprotein modifying it in plasmin (fibrinolysin); having thus fibrinolitic and anticoagulating effect. Fibrinolitic effect of drug is limited to blood clot, drug practically does not influence other mechanisms of a hemostasis (does not destroy fibrinogen, does not activate a system fibrinolysis) in this connection the risk of development of bleedings against its reception does not increase and the hypofibrinogenemia does not arise.

When developing an acute thrombembolia of a pulmonary artery which is followed by disturbance of a hemodynamics administration of drug promotes reduction, during a short period, the size of blood clot, normalization of pulmonary pressure and to preservation of physiologically normal work of a right ventricle.


Drug during short time is removed from a blood-groove. The elimination half-life makes about 5 minutes, that is, in blood in 20 min. there are about 10% of initial concentration. The remained dose of an alteplaza which is distributed in fabrics and liquids of an organism is removed within 40 minutes. Biotransformation of drug occurs in a liver.

Indications to use


High sensitivity to drug, TsNS new growths, hemorrhagic diathesis, diseases which are followed by disturbance of blood circulation of a brain (a stroke hemorrhagic, intracraneal hemorrhage), aneurism of vessels, surgical interventions on a spinal cord, a retinopathy hemorrhagic, the general operations, obstetric delivery, the expressed arterial hypertension, a pericardis, an endocarditis bacterial, pancreatitis, a peptic ulcer in an aggravation stage, a liver failure, portal hypertensia, cirrhosis, a varicosity of venous vessels of a gullet, hepatitis.

To appoint drug to Aktiliza with care in the presence of states which are followed by high risk of development of bleeding (a puncture of vessels, a biopsy, an injection in oil), pregnancy, a lactation, children's and advanced age.

Side effects

Local outside bleeding from the damaged vessels, places of a puncture, gums, a nose, internal bleeding (in an urinogenital path, a gastrointestinal tract, parenchymatous bodies), arrhythmia, is rare — nausea, vomiting, a trombotichesky embolism, lowering of the ABP.

To Aktiliza, application instruction (Way and dosage)

Preparation of solution for infusions: bottle contents with drug should be dissolved in contents of the second bottle from a set (water sterile) to concentration of 1 mg/ml. Further, for cultivation of this solution it is possible to use normal saline solution. The drug is administered intravenously. The dosage is defined depending on a disease, weight and a condition of the patient.

At a myocardial infarction in the acute period (the first 6 hours) the drug is administered by the patient weighing more than 65 kg in/in struyno, in a dose of 15 mg, further — infusion of 50 mg within half an hour and 35 more mg for one hour to a dose of 100 mg. In 6–12 hours after emergence of symptoms infusion of 50 mg and each 30 min. on 10 mg before achievement of the general dose of 100 mg during the 3rd hour is entered in/in struyno in a dose of 10 mg, then, within the first hour. For patients weighing less than 65 kg the general maximum dose of the administered drug should not be more than 1,5 mg/kg. Heparin and acetylsalicylic acid is in parallel entered. At treatment by drug control of the activated tromboplastinovy time is necessary for Aktiliza.

At treatment of a thromboembolism of a pulmonary artery to Aktiliza enter in/in struyno in a dose of 10 mg in 1–2 minutes and further in a dose of 90 mg in 2 hours, to the general dosage of 100 mg. For patients weighing less than 65 kg the general maximum dose of the administered drug should not be more than 1,5 mg/kg.


It is shown by hemorrhagic complications in the form of outside and internal bleeding.


Use to Aktiliza with other HP exerting impact on coagulability of blood or function of thrombocytes increases risk of development of bleeding. At a concomitant use of drug with APF inhibitors the risk of development of anaphylactic reactions increases. At infusion Aktiliza is forbidden to mix it in the same capacity with other HP.

Terms of sale

Prescription issue.

Storage conditions

To store drug at a temperature up to 25 °C. No more days are authorized to store solution, ready to use, in the refrigerator.

Period of validity

3 years.

Analogs Aktiliza

Coincidence on the ATH code of the 4th level:


About Aktiliz

Reviews of doctors of drug in the majority positive. Drug to Aktiliza has a number of essential advantages at the heart of which — a drug fibrinospetsifichnost. As on it antibodies are not developed, drug can be reused, it seldom causes arterial hypotonia.

Use to Aktiliza at a heart attack if treatment is begun at once (in the first 6 hours) allows to lower rates of mortality significantly. Besides, use to Aktiliza allows to avoid in most cases heavy complication of a myocardial infarctioncardiogenic shock.


  • To Aktiliza lyophilisate for preparation of solution for infusions of 50 mg No. 1 a bottle + solvent 50mlberinger Ingelkhaym of Farm Gmbh and KOKG
to show still


  • Aktilizeboehringer Ingelheim Pharma (Germany)


  • To Aktiliza time. baby inf. mg solution 50 50mlmerkle
  • To Aktiliza time. baby inf. mg solution 50 50mlmerkle
  • To Aktiliza time. baby inf. mg solution 50 50mlmerkle
Section: Cardiological Cardiovascular
in more detail

Education: Graduated from Sverdlovsk medical school (1968 - 1971) as "Paramedic". Graduated from the Donetsk medical institute (1975 - 1981) as "An epidemiologist, a hygienist". Passed postgraduate study in the Central scientific research institute of epidemiology Moscow (1986 - 1989). An academic degree – the candidate of medical sciences (degree is awarded in 1989, protection – the Central scientific research institute of epidemiology Moscow). Numerous advanced training courses are studied in epidemiology and infectious diseases.

Experience: Work as the manager of department of disinfection and sterilization of 1981 - 1992. Work as the manager of department of especially dangerous infections of 1992 - 2010. Teaching activity at Medical institute 2010 - 2013.

PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use to Aktiliza surely consult with the attending physician.